Medical Oncologist
CION Cancer Clinics
Why MSH6 risks are lower and start later | CION Cancer Clinics
MSH6 cancer risks are lower and appear later than with MLH1 or MSH2, because another repair protein partly covers for the missing one and because newer studies follow ordinary carriers rather than the most affected families. Lower does not mean low. This page explains the reasons, why older figures look so much worse, and what the difference changes for screening. At CION Cancer Clinics, our oncologists explain what a gene result means for you and your family, and plan the checks that follow.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Why are MSH6 risks lower and later than other Lynch genes?
- What explains the milder MSH6 picture?
- Why older MSH6 figures look so much worse
- The terms your counsellor may use
- What lower and later changes, and what it does not
- What this page cannot tell you
- Four ways lower risk gets misread
- Common questions about lower MSH6 risk
The short answer
Why are MSH6 risks lower and later than other Lynch genes?
Mainly because another protein can partly cover for MSH6 when it is missing, so DNA errors build up more slowly. It also reflects better research. Older studies looked at the most heavily affected families and overstated the risk. Newer studies that follow ordinary carriers over time show lower figures and later ages at diagnosis.
A partial backup inside the cell
MSH6 normally pairs with MSH2 to find copying mistakes. A related protein, MSH3, also pairs with MSH2 and handles some of the same kinds of error. When MSH6 is lost, MSH3 keeps part of the proofreading going. The cell is not fully protected, but it is not left defenceless either.
What lower does not mean
Lower is a comparison with MLH1 and MSH2, two of the higher-risk Lynch genes. It is not a comparison with the general population. An MSH6 carrier still has a clearly raised risk, especially of cancer of the womb lining, and still needs a screening plan.
Lower and later changes when screening starts. It does not change whether screening is needed.Four reasons
What explains the milder MSH6 picture?
Some of this is biology and some is how the research was done. Both matter when you read a risk figure.
The backup partner
MSH3 can take over part of the MSH6 job, especially spotting small loops of extra DNA letters. Some mistakes still slip through, but fewer than when MLH1 or MSH2 is lost.
Errors build up more slowly
Because repair is only partly lost, a cell takes longer to collect the mistakes that turn it cancerous. That delay shows up as cancers appearing later in life.
What that looks like in families
- Diagnoses in the fifties and sixties
- Fewer affected relatives per generation
- Tumour tests that look only mildly abnormal
Older studies overstated risk
Early research recruited families referred because they had many cancers. Those families were never typical. Following all carriers forward in time gives a fairer and lower picture.
The womb is the exception
Womb cancer risk stays substantial for women with MSH6, close to the other Lynch genes in some studies. Researchers do not yet fully understand why the womb lining is so sensitive to this gene.
Not sure whether this applies to you?
Ask an oncologistHow the picture changed
Why older MSH6 figures look so much worse
-
Lynch syndrome was found through very affected families
The condition was first described in families with bowel cancer in generation after generation, often at young ages. Those families set the early picture of what Lynch looked like.
-
MSH6 was added to the list
When MSH6 was linked to Lynch syndrome, its first carriers were found in the same kind of heavily affected family. The risks quoted at the time reflected that.
-
Doctors began testing every tumour
Many centres now check bowel and womb tumours for lost repair proteins, whatever the family history. This found MSH6 carriers in families nobody would have suspected.
-
Carriers were followed forward in time
Large international databases began tracking carriers already under screening. These showed lower figures for MSH6 and later ages at diagnosis than the early studies.
-
Guidelines caught up
Several guidelines now start bowel screening for MSH6 carriers later than for MLH1 or MSH2 carriers. Advice is still being refined as more data arrive.
Words behind the science
The terms your counsellor may use
- MSH3
- A repair protein that works alongside MSH2. It can partly cover for a missing MSH6, which softens the effect of the fault.
- Penetrance
- How often a fault actually leads to cancer across everyone who carries it. MSH6 has lower penetrance than MLH1 or MSH2.
- Ascertainment bias
- A distortion that happens when a study only includes the families that came to attention, usually the most affected ones.
- Prospective study
- Research that follows carriers forward in time rather than looking back at who got cancer. It gives fairer risk figures.
- Universal tumour screening
- Checking every bowel or womb tumour for lost repair proteins, whatever the family history. It finds many milder MSH6 families.
- Amsterdam criteria
- An older checklist of family history used to suspect Lynch syndrome. Many MSH6 families do not meet it.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
In practice
What lower and later changes, and what it does not
What it can change
What stays the same
Bowel screening may start a few years later
Regular colonoscopy is still recommended
Surgery on the womb may be timed later
Womb risk still needs a clear plan
Anxiety for younger relatives may ease
Each child has a one in two chance of inheriting it
A late diagnosis now makes more sense
Relatives should still be offered testing
Being straight with you
What this page cannot tell you
It cannot tell you how much lower your own risk is. Some MSH6 variants may behave differently from others, and some families carry more risk than the average suggests. What your specific variant means is a question for the counsellor who ordered the test.
The science is still settling
The backup explanation is well supported in the laboratory, but it does not explain everything, including the high womb risk. Most carrier databases are built from European and American families. Indian data are limited, and differences in diet, infection and screening access may shift the picture here.
Who this does not apply to
This page is about people with a confirmed harmful MSH6 fault. It does not apply to a variant of uncertain significance, which is managed on family history alone. It also does not apply to a tumour that lost MSH6 only inside itself, which is a question for targeted therapy.
If a relative was told their family is lower risk, check that this came from a genetics clinic, not from a search.Commonly believed
Four ways lower risk gets misread
"Lower risk means we can skip screening."
MSH6 risk is lower than some Lynch genes but still well above the general population. Skipping colonoscopy loses the main benefit of knowing you are a carrier.
"Cancer starts later, so the young ones need not test."
Testing adult children early lets them plan, decide on family, and start screening on time. Knowing early is different from worrying early.
"Our family is mild, so the womb risk must be small too."
Womb risk remains substantial with MSH6, even in families with little bowel cancer. Women carriers should still discuss symptoms and surgery timing with a gynaecologist.
"The doctors changed the figures, so nobody really knows."
The figures changed because better studies followed more carriers. Estimates are now more accurate, not less. Your counsellor uses the most current ones.
Questions we are asked
Common questions about lower MSH6 risk
Is MSH6 a low-risk gene?
It is better described as a moderate-to-high risk gene with milder effects than MLH1 or MSH2. Womb cancer risk in women remains significant. Treating it as low risk can lead families to drop screening that genuinely helps.
Why does my report say risks are lower than what I read online?
Many websites still quote older studies of heavily affected families. Current estimates come from large databases that follow carriers over time. Your counsellor's figures are usually the more up-to-date ones.
Does later risk mean I can start colonoscopy later?
Often a little later than for MLH1 or MSH2 carriers, yes. The exact start depends on your guideline and on the youngest bowel cancer in your family. If a relative was diagnosed young, screening may start earlier.
Why is womb risk still high if MSH6 is milder?
Researchers do not fully know. The womb lining seems particularly dependent on MSH6 for repair. Whatever the reason, guidelines treat womb risk seriously for MSH6 carriers and include a gynaecology plan.
Can some MSH6 families be higher risk than average?
Yes. Some families have more cancers or younger diagnoses than the average suggests. Other genes and shared habits may play a part. Your plan is shaped by your own family history as well as the gene.
Is MSH6 easier to miss on tumour tests?
It can be. Tumours from MSH6 carriers sometimes show only weak instability on MSI testing. A stain for the repair proteins usually shows MSH6 loss more reliably, and a blood test confirms whether it is inherited.
Does milder risk affect insurance?
India has no specific law protecting people from genetic discrimination in insurance, and insurers do not grade genes. Raise the question with your counsellor before testing, and consider arranging cover beforehand if it matters to your family.
Will the advice for MSH6 carriers change again?
Probably, as larger studies report. That is normal and a sign of better evidence. Ask your counsellor how you will hear about changes, and review your plan every few years or after a new diagnosis in the family.
Your Specialists
Meet CION's oncologists. Bring your family history or genetic report to them.
Our medical oncologists see people with a strong family history of cancer, arrange genetic counselling and testing where it fits, and plan the checks that follow.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- Prospective Lynch Syndrome Database — PLSD: cancer risks for Lynch syndrome carriers
- GeneReviews (NCBI) — Lynch Syndrome
- MedlinePlus Genetics — MSH6 gene
- National Cancer Institute — Genetics of Colorectal Cancer (PDQ) – Health Professional Version
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Confused by different MSH6 risk figures?
A genetic counsellor can explain which estimates apply to your family and what they mean for screening. We will not push you towards tests you do not need. One helpline serves every CION centre.